Clinical Trial

Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program

Recruiting
View on ClinicalTrials.gov →
Summary
The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2024-10-09; most recent amendment 2026-07-01.
Status change: Not Yet Recruiting → Recruiting 2024-11-21
Trial Details
NCT Number NCT06636383
Lead Sponsor Ultragenyx Pharmaceutical Inc
Conditions Glycogen Storage Disease Type Ia
Enrollment 140 participants
Start Date 2024-11-04
Primary Completion 2036-12 (estimated)
Study Completion 2036-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-06